---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Dosage"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Dosage. Topics: FORTIFI-HN01 pivotal regimen, Doses studied in the phase 1b first-line HNSCC expansion cohorts, Doses studied in the phase 1 dose escalation, Loading and every-3-week maintenance regimen under study in FORTIFI-FLEX, and 2 further topics. 6 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/dosage"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### FORTIFI-HN01 pivotal regimen

| Arm | Regimen |
| --- | --- |
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 optimal biological dose arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |
| Phase 3 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

> “Patients receive pembrolizumab (200 mg IV every 3 weeks for up to 35 cycles) and either ficerafusp alfa or placebo IV QW until disease progression or unacceptable toxicity.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

> “In January 2026, we announced that we selected 1500mg QW of ficerafusp alfa in combination with pembrolizumab as the optimal dose for Phase 3 portion of the FORTIFI-HN01 pivotal trial.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-2.1.2.10.1-2"></a>

### Doses studied in the phase 1b first-line HNSCC expansion cohorts

| Cohort | Ficerafusp alfa | Pembrolizumab |
| --- | --- | --- |
| 750 mg weekly | “Ficerafusp alfa 750 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 1500 mg weekly | “Ficerafusp alfa 1500 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 2000 mg every 2 weeks | “Ficerafusp alfa 2000 mg Q2W” | “Pembrolizumab 400 mg Q6W” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.10.1-3"></a>

### Doses studied in the phase 1 dose escalation

> “At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).”
> “The MTD was not reached in either cohort.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-2.1.2.10.1-4"></a>

### Loading and every-3-week maintenance regimen under study in FORTIFI-FLEX

| Arm | Regimen |
| --- | --- |
| Arm A | “Loading phase (12 weeks): Ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” “Maintenance phase: Ficerafusp alfa 2250 mg Q3W (alternative dose) + pembrolizumab 200 mg Q3W.” |
| Arm B | “Continuous ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

> “In August 2026, we announced the initiation of FORTIFI-FLEX, a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg QW followed by maintenance dosing of 2250mg every three weeks as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-2.1.2.10.1-5"></a>

### Dose modification rules in the phase 1b

> “Pembrolizumab was interrupted or discontinued (dose reduction not permitted) for grade ≥3 immune-related adverse events (AEs) per investigator assessment.”
> “Grade ≥3 AEs resulted in interruption, dose modification (ficerafusp alfa only), or permanent discontinuation according to study drug attribution.”
> “Patients who discontinued one study drug for any reason other than disease progression could continue the other per investigator discretion.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.1.2.10.1-6"></a>

### Pembrolizumab labeled dosage for HNSCC

> “HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks.”
> “Until disease progression, unacceptable toxicity, or up to 24 months”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
